Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

A perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged AML

Sajesan Aryal, Brittany Curtiss, Xinyue Zhou et al. Nov 03, 2025 pp. 1707-1707 10.1182/blood-2025-1707

Abstract Introduction: KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) is characterized by epigenetic dependencies, yet it often rem...

Geriatric assessment in hematology (GAH) scale for survival prognostication and early treatment discontinuation in older adults: Final results from the spanish hematogeriatric registry

Isabel González-gascón-y-Marín, Dolly Viviana Fiallo Suarez, Maite Antonio-Rebollo et al. Nov 03, 2025 pp. 6266-6266 10.1182/blood-2025-6266

Abstract Introduction: Comprehensive geriatric assessment (CGA) is the “gold standard” for determining frailty in older patients with hemato...

Peripheral blast count at apheresis as a risk factor for survival following tisagenlecleucel in children and young adults

Kaylyn Lyons, Kristen Miller, Arpita Deb et al. Nov 03, 2025 pp. 7638-7638 10.1182/blood-2025-7638

Abstract Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignancy. Relapsed or refractory (R/R) B-ALL c...

Impact of antibiotic exposure on CAR-T cell therapy outcomes: Analysis in multiple Myeloma and lymphoma

Bin Lv, Lingling Yin, Ying Wang et al. Nov 03, 2025 pp. 4071-4071 10.1182/blood-2025-4071

Abstract Background: The gut microbiome is known to play a significant role in cancer immunotherapy. Antibiotic use can disrupt the intestina...

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Vikas Gupta, Francesca Palandri, Jean-Jacques Kiladjian et al. Nov 03, 2025 pp. 3809-3809 10.1182/blood-2025-3809

Abstract Introduction: Myelofibrosis (MF) is characterized by splenomegaly, constitutional symptoms, and cytopenias such as anemia and thromb...

Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection

Kristina Nasr, Yan Zou, Shahzad Raza et al. Nov 03, 2025 pp. 3969-3969 10.1182/blood-2025-3969

Abstract Fat pad biopsies (bx) are routinely used in the diagnostic work-up for AL amyloidosis due to their feasibility and low complication...

Distinct and non-overlapping epigenetic signatures differentiate MPN subtypes and reveal hydroxyurea-induced remodeling

Sigal Avraham, Miriam Neaman, Jasline Deek et al. Nov 03, 2025 pp. 3765-3765 10.1182/blood-2025-3765

Abstract Background Myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (...

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis

Jingbo Yu, Nicole Engel-Nitz, Mary DuCharme et al. Nov 03, 2025 pp. 2452-2452 10.1182/blood-2025-2452

Abstract Background: Ruxolitinib (RUX) is an oral, selective Janus kinase (JAK)1/JAK2 inhibitor approved for chronic graft-versus-host disea...

Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin

Francesca Albano, Sabrina Browning, Fangyong Li et al. Nov 03, 2025 pp. 7578-7578 10.1182/blood-2025-7578

Abstract Background: NCT05002816 is an ongoing phase Ib/II trial evaluating the safety, tolerability and preliminary efficacy of the unique...

Loss-of-function alterations in TRAF3 drive BTK/PLCG2-independent ibrutinib resistance in CLL

Bharath Dileep Kumar, Rohan Herur, Victoria Rogness et al. Nov 03, 2025 pp. 434-434 10.1182/blood-2025-434

Abstract Bruton's tyrosine kinase inhibitors (BTKis) have transformed the treatment of Chronic Lymphocytic Leukemia (CLL), yet many patients...

Real-world changes in CLL treatment patterns following collaborative educational initiatives delivered in community settings

Carmine Deluca, Michael Beyer, Marina Wanes et al. Nov 03, 2025 pp. 6430-6430 10.1182/blood-2025-6430

Abstract Background: Modern therapeutics in use for chronic lymphocytic leukemia (CLL), including covalent BTK inhibitors (cBTKi), time-limi...

Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913

Deepa Jeyakumar, An To, Piyanuch Kongtim et al. Nov 03, 2025 pp. 5241-5241 10.1182/blood-2025-5241

Abstract Intro Secondary acute myeloid leukemia (sAML) from antecedent hematologic disorders or prior cytotoxic therapy is associated with a...

Clinicopathological characteristics of high-grade B-cell lymphomas through  Bone marrow evaluation

Yani Lin, Xiaoyan Li, Enbin Liu et al. Nov 03, 2025 pp. 5453-5453 10.1182/blood-2025-5453

Abstract High-grade B-cell lymphoma (HGBCL) is primarily diagnosed and classified through tissue biopsy. However, in a small subset of cases...

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Julio Chavez, Jason Westin, Javier Muñoz et al. Nov 03, 2025 pp. 1006-1006 10.1182/blood-2025-1006

Abstract Introduction While outcomes in patients with R/R FL have improved with T-cell–redirecting treatments (e.g. CAR...

Adverse outcomes of acute pericarditis in patients with active multiple myeloma: Insights from a national inpatient cohort

Amro Awad, Yogitha Posani, Rami Awad et al. Nov 03, 2025 pp. 7939-7939 10.1182/blood-2025-7939

Abstract Background: Current literature suggests that patients with hematologic malignancies are predisposed to poorer cardiovascular diseas...

Rural-urban disparities in survival rates in adult Hodgkin lymphoma: A population-based study

Khaled Elhusseiny, Alaa Mahmoud, Xuan Chen et al. Nov 03, 2025 pp. 3625-3625 10.1182/blood-2025-3625

Abstract Introduction Hodgkin's lymphoma is known to have favorable survival outcomes; however, limited data exist regar...

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Jing-Zhou Hou, Tejvir Singh, Wesley Falconer et al. Nov 03, 2025 pp. 7934-7934 10.1182/blood-2025-7934

Abstract Background: Given the introduction of 2nd generation safer and more tolerable BTKis to treat first- line Chronic Lymphocytic Leukem...

A prospective study reveals feasibility and merits of drug profiling-guided precision therapy for children with high-risk leukemias

Yaqun Xu, Wing Yan Leung, Han Wang et al. Nov 03, 2025 pp. 5242-5242 10.1182/blood-2025-5242

Abstract Introduction Children with relapsed or refractory acute leukemias have limited treatment options and portend a dismal prognosis. Fu...

Modification of post-trogocytosis effects to Enhance CAR-t cell persistence

Jianxiang Wang, Haotian Ma, Heye Yu et al. Nov 03, 2025 pp. 810-810 10.1182/blood-2025-810

Abstract Trogocytosis is currently defined as a rapid membrane exchange process that occurs during cell-cell contact. Although widely report...

Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma

Mi Ding, Jianming Sun, Tongjun Liu et al. Nov 03, 2025 pp. 3302-3302 10.1182/blood-2025-3302

Abstract Background: Despite significant therapeutic advancements, multiple myeloma (MM) remains incurable. Most patients ultimately relapse...

Older adults with multiple myeloma can drive CAR safely

Kyle Hansotia, Subodh Bhatta, Don Benson et al. Nov 03, 2025 pp. 8139-8139 10.1182/blood-2025-8139

Abstract Introduction: Multiple myeloma (MM) is a bone marrow malignancy that predominantly involves older adults. CAR-T is a highly effecti...

Increased risk of venous thromboembolism and hypertensive disorders during pregnancy in sickle cell disease patients: A meta-analysis focused on actionable outcomes

Onajite Ifie, Nicki Hassibi, Teresa Jewell et al. Nov 03, 2025 pp. 2664-2664 10.1182/blood-2025-2664

Abstract There is a paucity of evidence-based interventions to improve outcomes in pregnancy in sickle cell disease (SCD) patients despite a...

Causal role of gut microbiota in immune thrombocytopenia: A systematic review of mendelian randomization studies

Kalan Patel, Bhaswanth Bollu, Juhi Chovatiya et al. Nov 03, 2025 pp. 6596-6596 10.1182/blood-2025-6596

Abstract Background Gut dysbiosis has been repeatedly linked to immune thrombocytopenia (ITP), but confounding and reverse causation hamper...

Lipid nanoparticle-based delivery of gene therapy targeting the RUNX1::RUNX1T1 fusion oncogene in acute myeloid leukemia

Johannes Sørensen, Carina Rosenberg, Katharina Wolter et al. Nov 03, 2025 pp. 7845-7845 10.1182/blood-2025-7845

Abstract Acute myeloid leukemia (AML) with RUNX1::RUNX1T1 was one of the first types of AML to be defined by a translocation leading to the...

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

Snegha Ananth, Jayasindhu Mallampet, Betty Chang et al. Nov 03, 2025 pp. 941-941 10.1182/blood-2025-941

Abstract Introduction: Circulating tumor DNA (ctDNA)-based measurable residual disease (MRD) assessment is a promising noninvasive biomarker...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page